» Articles » PMID: 20215064

Gastrointestinal and Hepatic Complications of Sickle Cell Disease

Overview
Specialty Gastroenterology
Date 2010 Mar 11
PMID 20215064
Citations 55
Authors
Affiliations
Soon will be listed here.
Abstract

Sickle cell disease (SCD) is an autosomal recessive abnormality of the beta-globin chain of hemoglobin (Hb), resulting in poorly deformable sickled cells that cause microvascular occlusion and hemolytic anemia. The spleen is almost always affected by SCD, with microinfarcts within the first 36 months of life resulting in splenic atrophy. Acute liver disorders causing right-sided abdominal pain include acute vaso-occlusive crisis, liver infarction, and acute hepatic crisis. Chronic liver disease might be due to hemosiderosis and hepatitis and possibly to SCD itself if small, clinically silent microvascular occlusions occur chronically. Black pigment gallstones caused by elevated bilirubin excretion are common. Their small size permits them to travel into the common bile duct but cause only low-grade obstruction, so hyperbilirubinemia rather than bile duct dilatation is typical. Whether cholecystectomy should be done in asymptomatic individuals is controversial. The most common laboratory abnormality is an elevation of unconjugated bilirubin level. Bilirubin and lactate dehydrogenase levels correlate with one another, suggesting that chronic hemolysis and ineffective erythropoiesis, rather than liver disease, are the sources of hyperbilirubinemia. Abdominal pain is very common in SCD and is usually due to sickling, which resolves with supportive care. Computed tomography scans might be ordered for severe or unremitting pain. The liver typically shows sickled erythrocytes and Kupffer cell enlargement acutely and hemosiderosis chronically. The safety of liver biopsies has been questioned, particularly during acute sickling crisis. Treatments include blood transfusions, exchange transfusions, iron-chelating agents, hydroxyurea, and allogeneic stem-cell transplantation.

Citing Articles

Transsulfuration pathway activation attenuates oxidative stress and ferroptosis in sickle primary erythroblasts and transgenic mice.

Xi C, Pang J, Xue W, Cui Y, Jiang N, Zhi W Commun Biol. 2025; 8(1):15.

PMID: 39762627 PMC: 11704341. DOI: 10.1038/s42003-024-07424-7.


Gallbladder remnant: A potential source for biliary stones postcholecystectomy; a case report in a child with sickle cell disease.

Miri A, Abdessalam S, Powers A, Quiros-Tejeira R, Dike C JPGN Rep. 2024; 5(2):162-165.

PMID: 38756117 PMC: 11093913. DOI: 10.1002/jpr3.12039.


Hemoglobin scavenger receptor CD163 as a potential biomarker of hemolysis-induced hepatobiliary injury in sickle cell disease.

Kaminski T, Sivanantham A, Mozhenkova A, Smith A, Ungalara R, Dubey R Am J Physiol Cell Physiol. 2024; 327(2):C423-C437.

PMID: 38682236 PMC: 11427010. DOI: 10.1152/ajpcell.00386.2023.


Society for Maternal-Fetal Medicine Consult Series #68: Sickle cell disease in pregnancy.

Sinkey R, Ogunsile F, Kanter J, Bean C, Greenberg M Am J Obstet Gynecol. 2023; 230(2):B17-B40.

PMID: 37866731 PMC: 10961101. DOI: 10.1016/j.ajog.2023.10.031.


Long-Term L-Glutamine Treatment Reduces Hemolysis without Ameliorating Hepatic Vaso-Occlusion and Liver Fibrosis in a Mouse Model of Sickle Cell Disease.

Katoch O, Ungalara R, Kaminski T, Li Z, Dubey R, Burholt I Biomedicines. 2023; 11(9).

PMID: 37760853 PMC: 10526062. DOI: 10.3390/biomedicines11092412.